Kendall Capital Management Acquires 4,146 Shares of AstraZeneca PLC (NASDAQ:AZN)

Kendall Capital Management increased its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 107.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,007 shares of the company's stock after purchasing an additional 4,146 shares during the quarter. Kendall Capital Management's holdings in AstraZeneca were worth $589,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Dynamic Advisor Solutions LLC raised its position in AstraZeneca by 58.4% during the first quarter. Dynamic Advisor Solutions LLC now owns 13,055 shares of the company's stock valued at $960,000 after buying an additional 4,811 shares during the period. Geode Capital Management LLC boosted its position in AstraZeneca by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 498,831 shares of the company's stock worth $32,683,000 after acquiring an additional 5,384 shares during the period. Dorsey & Whitney Trust CO LLC grew its stake in AstraZeneca by 0.5% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 35,300 shares of the company's stock valued at $2,313,000 after acquiring an additional 189 shares in the last quarter. Brandywine Global Investment Management LLC acquired a new position in shares of AstraZeneca in the 4th quarter valued at about $28,071,000. Finally, Farther Finance Advisors LLC lifted its position in shares of AstraZeneca by 13.1% in the first quarter. Farther Finance Advisors LLC now owns 6,083 shares of the company's stock worth $442,000 after purchasing an additional 706 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.

Analyst Upgrades and Downgrades

Separately, BNP Paribas started coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $85.00.

AstraZeneca Stock Up 2.3%

Shares of NASDAQ AZN traded up $1.58 during mid-day trading on Tuesday, reaching $71.46. The company had a trading volume of 6,729,924 shares, compared to its average volume of 5,222,788. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $87.68. The stock's 50 day moving average is $70.65 and its 200-day moving average is $70.55. The stock has a market capitalization of $221.62 billion, a PE ratio of 28.70, a price-to-earnings-growth ratio of 1.28 and a beta of 0.38.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The firm had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. During the same quarter in the previous year, the company posted $2.06 earnings per share. The business's quarterly revenue was up 7.2% compared to the same quarter last year. As a group, equities analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.